Neuvosyn

Neuvosyn is a biotechnology company dedicated to developing transformative small molecule therapies for neurodegenerative diseases by focusing on synaptic restoration. Launched by Apple Tree Partners (ATP), the company’s lead research program targets the Kidney and Brain Expressed Protein (KIBRA), which plays a crucial role in maintaining synaptic plasticity and memory. Neuvosyn aims to address the significant unmet need in Alzheimer’s disease and other dementias by repairing the functional connections between neurons rather than solely focusing on protein aggregation. Headquartered in Cambridge, Massachusetts, the company leverages a proprietary discovery platform and is led by a team of seasoned neuroscience industry veterans.